Slide 1: Glenmark Life Sciences cover and exchange filing letter
8 qlenma~k LIFE SCIENCES Partnership. Innovation. Pass ion . July 25, 2024 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400
Slide 2: Investor Presentation Q1 FY25
Investor Presentation Q1 FY25
Slide 3: Financial Performance Review
Financial Performance Review
Slide 4: Q1FY25 Highlights
Q1FY25 | Highlights “We are pleased to report broad-based revenue growth for the quarter, where, as anticipated, growth has picked up sequentially. Our Generic API business experienced a Dr. Yasir Rawjee robust 10.5% QoQ and 6.2% YoY growth. YoY growth was led by Europe, LATAM and Managing Director
Slide 5: Q1 FY25 Performance
Q1 FY25 Performance PAT Revenue EBITDA EBITDA PAT EPS (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) PAT Margin (In ₹) EBITDA Margin 11.05 5,954 33.7% 23.4% 9.69 9.69 20.7% 30.4% 19.9% 28.0% 18.3% 18.9% 5,785 29.0% 26.9% 1,355 5,728 1,950 7.99 1,188 1,187 1,742 1,725 979 1,446 5,366 Q1 Q2
Slide 6: P&L Highlights | Q1 FY25
P&L Highlights | Q1 FY25 Particulars (In ₹ Millions) Q1 FY25 Q4 FY24 QoQ Q1 FY24 YoY FY24 Revenue from Operations 5,886 5,366 9.7% 5,785 1.8% 22,832 Gross Profit 3,008 2,979 1.0% 3,304 -9.0% 12,812 Gross Profit (%) 51.1% 55.5% 57.1% 56.1% Other Income 55 31 75.4% 18 205.1% 120 Employee Benefits Expe
Slide 7: Healthy Returns Indicators
Healthy Returns Indicators ROICE Fixed Assets Turnover Working Capital Days 40% 170 176 166 167 36% 3.4 152 34% 33% 3.3 31% 2.9 2.7 102 107 104 99 89 120 116 136 122 125 -43 -53 -59 -62 FY21 FY22 FY23 FY24 Q1FY25 FY21 FY22 FY23 FY24 Q1FY25 -72 • ROICE is tracking at ~31% – Higher capital employed dr
Slide 8: Financial Performance Track Record
Financial Performance Track Record Robust growth and profitability indicators over the years Revenue EBITDA PAT EPS (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹) EBITDA PAT EBITDA Margin PAT Margin 21.6% 20.6% CAGR 10.4.% 20.4% 31.5% 19.7% 30.6% 31.4% 31.1% 30.1% 22,832 18.6% 4,670
Slide 9: Business Performance Review
Business Performance Review
Slide 10: Segment Performance | Generic & CDMO business
Segment Performance | Generic & CDMO business Generic API CDMO (Rev enu e In ₹ Milli o n s) (Rev enu e In ₹ Milli o n s ) 5,428 5,354 5,105 5,042 464 355 354 4,846 253 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 • Generic API revenues in Q1FY25 increased by • CDMO
Slide 11: Segment Performance | GPL vs. Non-GPL
Segment Performance | GPL vs. Non-GPL Non-GPL GPL GPL Non-GPL (In ₹ Milli o n s) (In ₹ Milli o n s) % of Total Revenue % of Total Revenue 73.1% 3,954 4,187 68.9% 3,821 33.9% 33.5% 33.4% 31.1% 3,699 1,964 2,000 66.6% 26.9% 66.1% 66.5% 1,667 1,541 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q1 FY24 Q2 FY2
Slide 12: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Area Mix 20% 19% 17% 16% 22% 34% 32% 31% 33% 38% 5% 6% Others 6% 6% 3% 5% 5% Emerging 4% 4% 5% Pain Management Markets 17% 15% 18% 11% 16% Diabetes 80% 81% 83% 84% 78% CNS Regulated Markets CVS 43% 43% 41% 41% 38% Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24
Slide 13: Company Overview
Company Overview LIFE SCIENCES
Slide 14: Global Footprint
Global Footprint • Filed 532 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 70+ 370+ 30+ 107 136 165 10+ 18 125+ 10+ 50+ 22 84 (Brazil) India – Mix of Regulated Number of Number of customers As of June 30, 2024 R
Slide 15: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend North (In ₹ Milli o n s) Therapy Europe Japan Brazil Australia ROW Total America R&D Spend CVS 38 36 4 21 10 35 144 As % to Sales CNS 38 25 8 15 2 19 107 Diabetes 10 5 - 8 - 14 37 3.3% Pain Management 1 2 - 4 1 9 17 3.0% 3.0% 753 Others 78 39 6 36
Slide 16: Quality-focused, compliant manufacturing & R&D infrastructure
Quality-focused, compliant manufacturing & R&D infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Last USFDA Location Approvals Mahape, Navi Mumbai Capacity Inspection Date USFDA, MHRA (UK), FIMEA R&D for new product (Finland), Romania (Europe) PMDA development and com
Slide 17: Strategy Going Forward
Strategy Going Forward / LIFE SCIENCES
Slide 18: Strategic Growth Levers
Strategic Growth Levers 1 Gx API Business New product launches Geographical expansion New Growth levers 2 Focus on new markets becoming more regulated Pursue 2nd source opportunities with top generic players CDMO Ramp up Expand into complex API platforms Iron compounds Oncology & HP
Slide 19: Future Capacity Expansion Plan
Future Capacity Expansion Plan Operational Expansion Type Division Location Status & Planned Capacity Timelines 208 KL (Construction Completed) Q2 FY25 Brownfield API / Intermediate Ankleshwar Planned addition of 60KL Pharma Capacity FY26 18 KL Pharma Capacity (Construction Completed) Q2 FY25 Brownf
Slide 20: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@glenmarklifesciences.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE RUNJHUN JAIN Email: Diwakar.Pingle@in.ey.com Email: Runjhun.Jain1@in.ey.com CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68297979 4th Floor, OIA House, 4